Compare AbbVie Inc (ABBV) vs Wix.Com Ltd (WIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Wix.Com Ltd — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Wix.Com Ltd trades at $47.53 (market cap $2.11B). The key difference: AbbVie Inc is far larger — about 213.2× Wix.Com Ltd's market cap, and AbbVie Inc pays a 2.72% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| ABBV | WIX | |
|---|---|---|
Market Cap | $449.91B | $2.11B |
Sector | Health | Technology |
52-Week High | $261.07 | $184.24 |
52-Week Low | $184.85 | $40.43 |
Enterprise Value | $513.38B | $1.67B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
WIX trades at $50.36, up 2.05% today, amid mixed signals. The stock shows strong revenue growth, reaching $1.99B in 2025, but profitability remains inconsistent with a net margin of -1.97%. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Technical indicators are bullish overall, with RSI suggesting mild overbought conditions. Positive news includes partnerships with Elavon and Microsoft, though legal investigations pose headwinds.
Outlook: Analyst consensus is bullish with a $83.13 price target, but risks include legal scrutiny and volatile earnings. Investment opportunity lies in revenue growth and strategic partnerships, countered by profitability challenges and potential legal liabilities. Near-term performance hinges on Q2 2026 earnings and resolution of investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
